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ABSTRACT  
Malignant tachyarrhythmias, ventricular fibrillation (VF) and tachycardia (VT), associated with ischemia/reperfusion (I/R) 
injury represent a major cause of sudden cardiac death worldwide. Pharmacological modulation of the cardiac 
ATP-sensitive potassium channels, either sarcolemmal (sarcKATP) or mitochondrial (mitoKATP), has been reported by 
many (but not all) studies to be cardioprotective against the deleterious effects of postischemic reperfusion. The aim of 
the present study was to assess the effects of HMR-1098 (10 μΜ), a cardioselective sarcKATP inhibitor and of diazoxide 
(DZX, 50 μΜ), a mitoKATP opener, given either independently or together, on I/R-related arrhythmias. A brief episode 
of regional ischemia was elicited by ligation of the left anterior descending coronary artery (LAD) in 
Langendorff-perfused rat hearts (constant flow mode) and the compounds were given prior to the induction of ischemia. 
In separate administration, HMR-1098 and DZX significantly reduced the duration of reperfusion-related VF (but not of 
VT) as compared to the control group. Also, the incidence of both tachyarrhythmias was diminished (albeit not 
significantly) by the individual administration of these compounds. Intriguingly, neither isolated nor combined 
administration of HMR-1098 and DZX were able to significantly decrease the duration of ventricular tachycardia (VT). 
Moreover, in the presence of both compounds the beneficial effect on VF duration, recorded with each of the drug 
when given solely, was lost. In isolated rat hearts, the independent administration of a sarcKATP inhibitor and a 
mitoKATP opener mitigated the duration of reperfusion-induced ventricular fibrillation, whereas the association of these 
compounds did not influence the incidence and duration of malignant tachyarrhythmias.  
Keywords: isolated rat heart, sarcolemmal and mitochondrial ATP-sensitive potassium channels, ischemia-related 
malignant arrhythmias 
 
INTRODUCTION 
Ischemia-related ventricular tachyarrhythmias are 
currently the major cause of sudden cardiac death 
worldwide [1]. Preventing malignant arrhythmias in the 
setting of myocardial ischemia represents an unmet 
therapeutic target, ultimately aimed at decreasing mortality 
due to coronary artery disease [2]. The efficiency of current 
antiarrhythmic therapy is still under debate and a couple of 
studies have shown that several antiarrhythmic drugs can 
rather increase the risk of lethal arrhythmias in patients 
recovering after myocardial infarction [3]. The major 
mechanism underlying ventricular arrhythmias is 
represented by reentry, classically promoted by the 
heterogeneity in action potential duration (APD) and tissue 
repolarization, respectively. The duration of action potential 
can be influenced, among others, by the activity of the 
ATP-sensitive potassium channels (KATP) that couple 
membrane excitability with cellular energetics [4]. These 
channels were firstly described by Noma [5] in the 
sarcolemmal membrane of cardiomyocytes (sarcKATP). A 
decade later, Inoue et al. [6] described a second type of 
KATP channels located in the inner mitochondrial membrane 
(mitoKATP). The ATP-dependent potassium channels are 
closed during normoxic conditions, when the cellular level 
of ATP is high, and open when ATP concentration drops 
during myocardial ischemia, as a result of the accumulation 
of ischemic metabolites ADP, lactate and H+ [2].  
Paradoxically, both activation and inhibition of sarcKATP 
channels have been associated with antiarrhythmic effects 
[7]. In particular, opening the sarcKATP channels has been 
considered responsible for a significant potassium efflux 
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with the subsequent shortening of the APD and the 
increase in the incidence of re-entrant arrhythmias, 
respectively [3,7-9]. Accordingly, several studies suggested 
that inhibition of sarcKATP channels can protect the heart 
against ischemia/reperfusion-induced arrhythmias, and 
also improve the survival rates [10-12]. 
In the past 2 decades, studies have shifted to the 
investigation of mitoKATP channels as effectors of 
cardioprotection [13]. In this regard, opening the mitoKATP 
channels was found to preserve mitochondrial structure 
[14], increase ATP preservation during ischemia and the 
functional recovery at reperfusion [15], and also to 
decrease infarct size [16]. 
In the present study we thought to assess the effect of 
the combined administration of a cardioselective sarcKATP 
inhibitor and a mitoKATP opener on ischemia-induced 
arrhythmias in the isolated rat heart model.  
MATERIAL AND METHODS 
All the experiments were performed using a 
Langendorff retrograde perfusion system in the constant 
flow mode. The perfusion buffer Krebs-Henseleit (NaCl 
118.0 mmol/L; KCl 3.2 mmol/L; MgSO4 1.2 mmol/L; 
NaHCO3 25.0 mmol/L; NaH2PO4 1.18 mmol/L; CaCl2 2.5 
mmol/L; glucoză 11.1 mmol/L) was oxygenated with 
carbogen (95% O2, 5% CO2), at least 15 minutes prior to 
the experiment and kept at 370C and pH=7.4. All 
experimental procedures were conducted in accordance 
with the Directive 2010/63/EU and the Romanian Law nr. 
43/May 2014 concerning the protection of animals used for 
scientific purposes. The experimental protocol was 
approved by the Committee for Research Ethics of “Victor 
Babes” University for Medicine and Pharmacy of Timişoara, 
Romania. 
Most reagents were purchased from Sigma Aldrich.  
Experimental protocol  
Male Sprague-Dawley rats (n= 32) were anesthetized 
using a mixture of xylazine (5 mg/kg) and ketamine (30 
mg/kg). After the abdominal laparotomy, 500 IU of heparin 
was administered via the portal vein to prevent thrombosis. 
The heart was rapidly excised, rinsed with cold heparinized 
Krebs-Henseleit solution and mounted on the cannula of 
the Langendorff apparatus for the retrograde perfusion. 
After cannulation, hearts were allowed to stabilize for 3 
minutes prior being subjected to 8 minutes of regional 
ischemia followed by 10 minutes of reperfusion. Regional 
ischemia was elicited by the ligation of left anterior 
descending (LAD) coronary artery. A brief episode of 
non-necrotic ischemia was purportedly chosen in order to 
investigate the 'pure' antiarrhythmic effect, i.e unrelated to 
the death of the cardiomyocytes.  The compounds, 
HMR-1098 (10 μΜ) and DZX (50 μΜ) were dissolved in 
dimethyl sulfoxide (DMSO, final concentration less than 
0.05%) and added to the perfusate before the stabilization 
period. The experimental protocol is presented in Figure 1. 
  
 
Fig. 1. Experimental protocol.  
(A) Control group, (B) HMR-1098, (C) DZX, 
(D) HMR-1098 + DZX treated groups. 
Statistics 
Ventricular arrhythmic events were analyzed as 
incidence and duration expressed as log10 from the total 
reperfusion time (600s). Statistical analysis was performed 
using one-way ANOVA and Tukey’s test as Post-hoc 
comparison among the groups. A value of p<0.05 was 
considered statistically significant. 
RESULTS 
The present study was purported to assess the 'pure' 
antiarrhythmic properties of two KATP modulators, a 
sarcKATP inhibitor and a mitoKATP opener, and whether 
their combined administration might provide an additive 
effect. 
 
The Effects of HMR-1098 and DZX on 
Tachyarrhythmias Incidence 
The incidence of VT and VF in the study groups is 
shown in Table 1. The brief 10 min period of postischemic 
reperfusion was associated with VF in all animals and VT 
in 5 out of the 8 rats of the control group, respectively. A 
decreasing tendency in the incidence of both types of 
malignant arrhythmias in the presence of either KATP 
modulator when given independently was recorded. 
However, when given together, the incidence of both 
arrhythmias was comparable to the one of the control 
group (5 out of 8 animals for VT, and 7 out of 8 animals for 
VF) - Table I.  
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Table I. The incidence of VF and VT. 
  Control HMR-1098 DZX DZX+ HMR-1098 
VT  5/8  3/8  4/8  5/8 
VF 8/8  5/8  6/8 7/8 
Normal 
heart 
rhythm 
 2/8 8/8 7/8  6/8 
The Effects of HMR-1098 and DZX on 
Tachyarrhythmia Duration 
Surprisingly, neither the individual nor the combined 
administration of HMR-1098 and DZX were able to reduce 
the duration of VT as compared to controls (Figure 2).  
 
 
Fig. 2. The isolated and combined effects of HMR-1098  
and DZX on VT duration.  
(n = 8/group, p = NS) 
 
In contrast, inhibition of sarcKATP channels with the 
selective compound HMR-1098 and opening of mitoKATP 
channels with DZX was each followed by a significant 
decrease in the mean duration of VF (Figure 3). However, 
the association of both KATP modulators abolished the 
beneficial effect of the individual administration on VF 
duration (Figure 3).   
 
Fig.3. The isolated and combined effects of HMR-1098  
and DZX on VF duration. 
(n=8/group, **p<0.01 for HMR-1098 vs.  
Control, *p<0.05 for DZX vs. Control) 
 
DISCUSSIONS 
The major finding of this paper is that the sarcKATP 
inhibitor and the mitoKATP opener, albeit beneficial in 
individual administration against VF, were not able to 
diminish the incidence and duration of reperfusion-related 
ventricular arrhythmias when jointly given prior to the 
ischemic episode.  
The cardioprotective effects, including the 
antiarrhythmic ones, of KATP modulators were extensively 
[for recent comprehensive reviews see refs. 17, 18]. In 
particular, glibenclamide, a non-selective sarcKATP inhibitor 
belonging to the second generation of sulphonylureas, was 
systematically reported to prevent/reduce the incidence of 
arrhythmias in several in vitro and in vivo experimental 
models and also in the clinical arena [17, 22-23]. 
HMR-1098 is a sulfonylthiourea, reported as 
cardioselective blocker of cardiac sarcKATP channels by 
some (but not all) authors [24] that, at variance from 
glibenclamide, did not influence the blood glucose levels 
[25] or the coronary flow under normoxic and hypoxic 
conditions [26]. Conflicting results are available in the 
literature with respect to the antiarrhythmic action of 
HMR-1098. Accordingly, Fischbach et al. demonstrated 
that pre-treatment with 3 μΜ HMR-1098 was able to 
prevent the apparition of VF in isolated rabbit hearts, and 
also to block (at 1μΜ) the VF induced by pinacidil, a 
non-selective KATP agonist [27]. In the canine old 
myocardial infarction model, HMR-1098 (but not 
glibenclamide) improved the scores of programmed 
electrical stimulation-induced ventricular arrhythmias, as 
reported by Zhu et al. [28]. At variance, Gok et al. reported 
that HMR-1098 (3 and 30 μmol/l) was not able to prevent 
VT and VF in isolated rat hearts subjected to 30 min of 
coronary occlusion followed by 30 min of reperfusion [29].  
In our model of short I/R injury, we observed decrease in 
the incidence (but not the duration) of 
reperfusion-associated VT in the presence of HMR-1098. 
Conversely, both incidence and duration of VF were 
dimished, albeit statistical significance (P < 0.01, vs. 
control) was reached only in case of the latter. 
DZX is a benzothiadiazine with important 
cardioprotective properties that has been reported to exert 
antiarrhythmic effects in the rat model of I/R injury, both in 
vivo and in vitro [reviewed in ref. 17].  In our study, 
pre-treatment with DZX effects comparable to the ones of 
HMR-1098 with respect to the incidence and duration of VT 
and VF. Thus, in independent administration, DZX 
mitigated (albeit non-significantly) the incidence of both VT 
and VF, had no effect on VT duration, and significantly 
diminished the VF duration (P < 0.05, vs. control). 
Surprisingly, in combined administration, the KATP 
modulators had no beneficial effect on either incidence or 
duration of VT and VF. 
In the setting of I/R injury, cardioprotection associated 
with mitoKATP opening has been ascribed to the following 
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mechanisms: mitochondrial swelling, inhibition of ATP 
synthesis during ischemia, decreased mitochondrial Ca2+ 
overload, modulation of ROS production during ischemia 
and reperfusion, respiratory inhibition, and mild uncoupling 
- mechanisms that underlie the infarct size reduction and 
the increase in functional recovery at reperfusion [30]. In 
the literature there are only a few studies that examined 
the antiarrhythmic effect of mitoKATP opening. Thus, in 
anesthetized rabbits, two selective mitoKATP openers, 
nicorandil and minoxidil, when administered prior to 
regional ischemia of LAD, were able to increase the 
survival rate and decrease arrhythmogenesis, respectively 
[2]. In the canine model of in vivo I/R injury, DZX protected 
the myocardium against ischemia/reperfusion- induced 
arrhythmias, effect blocked by the administration of 5-HD, 
the classic mitoKATP blocker [31].  
Interestingly, the loss of mitochondrial selectivity has 
been reported during ischemia for both DZX and nicorandil, 
when they can activate sarcKATP as result of increased 
ADP concentration [32]. In line with this observation we 
can speculate that the loss of antiarrhythmic effects when 
associating DZX to HMR-1098 was the consequence of 
counteracting the effect of the latter on sarcKATP; however, 
we did not measure the ADP concentration to confirm that 
it was decreased. However, other mechanisms can be also 
incriminated since DZX has been reported to elicit 
KATP-independent effects in cardiomyocytes [33]. Further 
experiments aimed at assessing the particular effect of 
each drug on the sarcKATP channel activity are required.  
CONCLUSIONS 
In isolated rat hearts, the independent administration of 
a sarcKATP inhibitor and a mitoKATP opener mitigated the 
duration of reperfusion-induced ventricular fibrillation, 
whereas the association of these compounds did not 
influence the incidence and duration of malignant 
tachyarrhythmias.  
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CARACTERIZAREA EFECTELOR MODULATORILOR 
SARCKATP ȘI MITOKATP ASUPRA ARITMIILOR INDUSE 
DE REPERFUZIE PE INIMI IZOLATE DE ȘOBOLAN 
 
REZUMAT 
Tahiaritmiile maligne, fibrilația și tahicardia ventriculară (FV și TV) asociate ischemiei/reperfuziei (I/R) miocardice 
reprezintă o cauză majoră de moarte cardiacă subită la nivel global. Modularea farmacologică a canalelor cardiace de 
potasiu dependente de ATP localizate atât la nivel sarcolemal (sarcKATP) cât și la nivel mitocondrial (mitoKATP) a fost 
asociată cu cardioprotecție în condițiile ischemiei/reprefuziei miocardice în numeroase studii, fără însă ca această 
observație să fie fără echivoc. Scopul prezentului studiu a fost de a evalua efectele administrării izolate și în asociere a  
HMR-1098 (10 μΜ), inhibitorului selectiv al canalelor sarcKATP și respectiv, a diazoxidului (DZX, 50 μΜ), deschizătorului 
canalelor mitoKATP, asupra tahiaritmiilor induse de reperfuzia postischemică. Ischemia regională a fost indusă prin 
ligatura arterei coronare anterioare descendente stângi la nivelul inimilor izolate de șobolan perfuzate retrograd tip 
Langendorff (în modul de lucru cu flux constant), iar compușii au fost administrați anterior inducerii ischemiei regionale. 
În administrare independentă, atât HMR-1098 cât și DZX au redus semnificativ durata FV (dar nu și a TV) comparativ 
cu lotul martor. De asemenea, aplicarea lor individuală a redus (deși nu semnificativ) incidența ambelor tahiaritmii 
maligne. Surprinzător, nici administrarea independentă nici cea în asociere a compușilor nu au condus la o reducere 
semnificativă a duratei TV. Mai mult, administrarea combinată a condus la pierderea efectului benefic obținut în cazul 
aplicării individuale asupra duratei FV. În concluzie, în cazul inimilor izolate de șobolan, administrarea independentă a 
unui inhibitor al sarcKATP și respectiv, a unui deschizător al mitoKATP, a redus durata fibrilației ventriculare la reperfuzia 
postischemică, în timp ce asocierea acestor compuși nu a influențat incidența și durata tahiaritmiilor maligne.  
Cuvinte cheie: inimă izolată de șobolan, canale de poatasiu sarcolemale si mitocondriale dependente de ATP, aritmii 
maligne induse de ischemie 
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